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In Brief
In this article, Liebscher et al. provide in vitro and in vivo proof that members of the adhesion GPCR class are activated through a tethered peptide agonist, which they term the Stachel sequence. This raises the possibility of actively inducing adhesion GPCR function.
INTRODUCTION
Adhesion G protein-coupled receptors (aGPCRs) are among the largest proteins in nature and consist of a long extracellular domain (ECD), a seven-transmembrane domain (7TM), and an intracellular C-terminal tail (ICD) ( Figure 1A ; Bjarnadó ttir et al., 2004; McMillan et al., 2002) . Another feature of this class is an autoproteolytic cleavage event that occurs at the GPCR proteolytic site (GPS), located within the GPCR autoproteolysis-inducing (GAIN) domain, which cleaves aGPCRs into an N-terminal fragment (NTF) and a C-terminal fragment (CTF) (Araç et al., 2012; Figure 1A) . aGPCRs play essential roles in controlling cell and tissue polarity (Lawrence et al., 2007) and can modulate synaptic functions (O'Sullivan et al., 2012; Sü dhof, 2001) . Although increasing information about aGPCR relevance is being obtained from mutant animal models, human diseases, and variant-associated phenotypes, little is known about the molecular function, activation, and signal transduction of this receptor class (Langenhan et al., 2013; Liebscher et al., 2013) .
The first indirect functional data for G protein coupling by aGPCRs were obtained in studies of GPR56 by knockdown experiments involving G 12/13 /p115 RhoGEF pathway components (Iguchi et al., 2008 ). An intriguing observation was reported in a study of gpr126 mutant zebrafish (zf), which exhibit defects in peripheral myelination (Monk et al., 2009) . This phenotype was reversible through forskolin-induced cyclic AMP (cAMP) elevation, suggesting G s -protein coupling. Other studies provided direct evidence of G s -protein coupling by measuring intracellular cAMP levels induced by basal activity of the aGPCRs GPR133 (Bohnekamp and Schö neberg, 2011) and GPR126 . Furthermore, experiments with chimeric G proteins, stoichiometric titrations of the Ga s subunit and receptor, and Ga s subunit knockdown experiments (Bohnekamp and Schö neberg, 2011 ) strongly support G protein coupling for GPR133.
Although it is now clear that aGPCRs couple to G proteins, it remains unclear whether endogenous binding partners can induce activation of aGPCRs. Interestingly, several studies have described increased receptor activity when an N-terminal deletion mutant was expressed (Okajima et al., 2010; Paavola et al., 2011 Paavola et al., , 2014 Yang et al., 2011; see Figure 1A ). These observations led to the assumption that the ectodomain functions as an inverse agonist, although at least two scenarios for aGPCR activation have been proposed : (1) the ectodomain contains an inverse agonist that inhibits 7TM signaling; and (2) ligand binding at the ECD or NTF removal changes the conformation of an aGPCR and exposes a tethered agonist (Figures S1A and S1B).
To test these two models, we used the human (h) GPR126 and GPR133 to analyze the contribution of the ECD to receptor basal activity, because G s -protein coupling has been experimentally suggested for these aGPCRs (Bohnekamp and Schö neberg, 2011; Gupte et al., 2012; Mogha et al., 2013) . Systematic mutagenesis studies revealed tethered peptide sequences within the most C-terminal part of the ECD, which specifically activates G protein signaling via 7TM interactions in vitro. Finally, we performed loss-of-function and rescue experiments in zf gpr126 mutants to confirm the in vivo and evolutionarily conserved significance of the tethered agonist. Together, our results define a mechanism of aGPCR activation.
RESULTS

ECD Deletion Activates GPR126 and GPR133
First, we deleted the ECDs of hGPR126 and hGPR133 at their natural GPS cleavage sites and tested the mutants in cAMP assays. In these constructs, termed CTF(GPR126) and The extracellular domain (ECD) contains a signal peptide (SP) and the GAIN/GPS domain. aGPCRs also possess a 7TM domain and an intracellular domain (ICD). Autoproteolysis at the GPS yields an N-terminal fragment (NTF) and a C-terminal fragment (CTF). For immunological detection, all constructs were epitope tagged with an N-terminal HA epitope (yellow square) and a C-terminal FLAG epitope (green trapezoid). (B) hGPR126 and hGPR133 constructs (CTF and DGPS-CTF) lacking the NTF and ECD, respectively, were generated. Chimeric constructs were generated by fusing the N terminus of the human P2Y 12 receptor (green line) onto the GPR126 and GPR133 mutants. The red half-circle symbolizes the C-terminal portion of the GPS after its cleavage site. See also Table S1 . (C-E) cAMP levels from COS-7 cells transfected with WT and mutant GPR126 and GPR133. (C) P2Y 12 -CTF mutants have increased basal activity compared with the WT, and this is abolished in DGPS-CTF mutants. (D) The constitutive activity of P2Y 12 -CTF(GPR126) is increased by deletion of Thr 813 . Receptor activity is abolished when the first three or more aa after the cleavage site are deleted. (E) Single positions within the C-terminal GPS sequence were mutated in GPR126 and GPR133 to alanine as shown. See Figures S1C-S1F for expression studies of all constructs. Data are shown as means ± SEM of three independent experiments, each performed in triplicate. Empty vector (eV) served as the negative control (eV; cAMP level: 3.68 ± 2.54 nM). Statistics were obtained by two-way ANOVA and Bonferroni post hoc test: *p < 0.05; **p < 0.01; ***p < 0.001. CTF(GPR133), the NTF between the signal peptide and the GPS cleavage site was removed, but the ECD part located C-terminally to the GPS cleavage site remained attached to the 7TM (CTF in Figure 1B and Table S1 ). All mutants lacking the ECD displayed significantly increased basal activities in cAMP assays ( Figure 1C ), consistent with results from other NTF-deficient aGPCRs. Both mutants were poorly detected at the cell surface via hemagglutinin (HA)-tag staining ( Figure S1C ). Accordingly, total ELISA and confocal imaging revealed an absence of the HA tag in CTF(GPR126) constructs. However, confocal imaging of the C-terminal FLAG tag showed specific membrane fluorescence ( Figure S1D ). We therefore speculate that the HA tags in the CTF mutant constructs are processed during intracellular protein maturation, thereby precluding detection. Because the N termini of rhodopsin-like receptors can improve cell-surface expression and detection of other GPCRs (Bohnekamp and Schö neberg, 2011; Stä ubert et al., 2010) , we added an HA-tagged P2Y 12 N terminus to the residual ECD of the CTF mutants. This generated chimeric P2Y 12 -CTF(GPR126) and P2Y 12 -CTF(GPR133) receptors ( Figure 1B ), which enabled proper plasma membrane detection via HA-tag visualization ( Figure S1C ). As observed for the CTF constructs, P2Y 12 -CTF(GPR126) and P2Y 12 -CTF(GPR133) displayed high constitutive activity ( Figure 1C ). These results demonstrate that deletion of the NTF activates hGPR126 and hGPR133.
The ECDs of GPR126 and GPR133 Contain Agonistic Domains
We generated GPR126 and GPR133 mutants in which the entire ECD, including the entire GPS motif, was deleted or replaced by the N terminus of P2Y 12 (DGPS-CTF; P2Y 12 -DGPS-CTF; Figure 1B) . None of the constructs displayed constitutive activity ( Figure 1C ), although these chimeras were expressed at the cell surface ( Figure S1C ). These results argue against the inverse agonist model of aGPCR activation because constitutive activity caused by the release of an inverse agonist would not depend on the presence of the residual GPS motif. These results point toward an activation model that requires the residual GPS motif, and we hypothesized that the GPS sequence downstream of the cleavage site contains determinants required for receptor activation.
To identify this potential tethered agonist, we sequentially deleted amino acids (aa) C-terminal to the GPS cleavage site in GPR126. Functional analysis showed that while the most N-terminal aa (Thr 813 ; Figure 1B ) was not essential for receptor activation ( Figure 1D ), deletion of the first two, as well as larger deletions that removed aa following Thr 813 , abolished basal receptor activity. This abolishment was not due to expression changes, since total and cell-surface expression levels were not significantly different between the constructs ( Figure S1E ). To maintain correct aa length C terminal to the cleavage site, we exchanged several positions with alanine. Again, mutants with an exchange of position 813 retained constitutive activity, whereas the exchange of positions 815, 818, and 819 abolished activity in P2Y 12 -CTF(GPR126) ( Figure 1E ), but expression levels were not affected ( Figure S1F ). Mutagenesis studies at corresponding positions in P2Y 12 -CTF(GPR133) revealed almost identical results ( Figures 1E and S1F) . These experiments support the existence of a defined agonistic region C-terminal to the GPS.
A Tethered Peptide Activates GPR126
To demonstrate that the aa sequence C-terminal to the GPS cleavage site has agonistic properties, we tested peptides derived from this domain on P2Y 12 -DGPS-CTF(GPR126). Excitingly, systematic truncation of the peptide's C terminus revealed several agonistic peptides (Figure 2A ). The most efficient peptide, p16 (16 aa long), was used for further structure-function studies. N-terminal deletion of the first two aa abolished the agonistic abilities of p16 (p16-1 and p16-2; Figure 2A ). This does not contradict the results of Figures 1D and 1E , because in the original CTF mutants, the first aa were replaced by the P2Y 12 N terminus or by alanine. Thus, these changes are tolerated, whereas the deletions in p16 are not. N-terminal extension beyond the cleavage site by one (p16+1) or two to four (p16+2 to p16+4) aa showed reduced or no agonistic activity of p16, respectively ( Figure 2A ). This indicates that noncleaved aa upstream of Thr 813 are not part of the agonistic structure. In concentration-response curves, p16 displayed low potency (EC 50 > 400 mM) on both P2Y 12 -DGPS-CTF(GPR126) and wildtype (WT) GPR126 ( Figure 2B ), which can be explained by the natural 1:1 stoichiometry of the covalently bound agonist in its natural conformation. The higher cell-surface expression of WT GPR126 compared with P2Y 12 -DGPS-CTF(GPR126; Figure S1C) explains the increased efficacy of p16 on WT GPR126 activation. Time-course analyses of cAMP accumulation (Figure S2A) and GTPgS binding assays ( Figure S2B ) in response to p16 supported p16-induced G protein coupling in GPR126transfected cells. Note that eV-transfected cells showed residual cAMP accumulation ( Figure 2C ) and GTPgS binding, indicating endogenous expression of GPR126 in COS-7 cells. This was confirmed by RT-PCR ( Figure S2C ), cAMP assays ( Figure 2C ), and kinetic dynamic mass redistribution (DMR) measurements (Epic; Corning Life Sciences) with small interfering RNA (siRNA)-mediated knockdown of the endogenous GPR126 ( Figures S2D and S2E) .
The endogenous expression of GPR126 and the high sensitivity of the DMR technology enabled us to test p16 apart from heterologous overexpression systems. As shown in Figure 2D , p16 induced concentration-dependent cellular responses very similar to those found with isoprenaline and b-adrenergic receptor endogenously expressed in COS-7 cells. Mutation of position 6 (Leu 6 Ala) in p16 abolished the response ( Figure 2D ), confirming specificity. To identify functionally relevant positions in the peptide, we performed a systematic alanine scan ( Figure 2E ). As expected from our receptor mutagenesis data (Figures 1D and 1E) , the more N-terminal aa (positions +2 to +7) were required for agonistic activity, whereas positions +8, +10, +12, and +14 to +16 could be replaced with Ala and still show agonistic properties. These data are in line with a high evolutionary conservation of the N-terminal portion of this peptide sequence ( Figure S2F ). Interestingly, the peptide p16 Gly 4 Ala blocked p16-induced GPR126 activation at double concentration ( Figure 2F ), indicating that p16 Gly 4 Ala can compete with the p16 binding site. Together, these data support the notion that the tethered peptide p16 activates GPR126.
A Tethered Peptide Activates GPR133
To determine whether activation by a tethered peptide is common for aGPCRs, we performed similar studies with GPR133. The P2Y 12 -DGPS-CTF(GPR133) could be activated by a peptide derived from the 13 aa (p13) downstream of the putative cleavage site ( Figure 3A ). Concentration-response measurements of p13 revealed specific activity on P2Y 12 -DGPS-CTF(GPR133) and WT receptor (EC 50 > 400 mM; Figure 3B ). The derived peptides were highly specific for the aGPCR from which they originated: GPR133 p13 did not activate GPR126, and GPR126 p16 did not activate GPR133 ( Figure 3C ). Because the importance of GPS cleavage for aGPCR expression and activity has been the subject of controversy , we tested two cleavage-deficient mutants: GPR126T 841 A (Moriguchi et al., 2004) and GPR133H 540 R (Bohnekamp and Schö neberg, 2011) . Both mutants were expressed and activated by their respective peptides ( Figures S2G-S2I) , indicating that cleavage at the GPS is not required for aGPCR activation by the tethered agonistic peptides. These data demonstrate that the tethered peptide p13 activates GPR133. Together with our analysis of GPR126, these studies suggest that tethered peptide activation is a common signaling modality for the aGPCR class.
Tethered Peptide Activation of Gpr126 In Vivo
We next sought to test the in vivo relevance of aGPCR tethered peptide activation. For these studies, we used zf because previous mutant analyses demonstrated that Gpr126 is essential for Schwann cell myelination and ear development and that these physiological functions require cAMP elevation (Geng et al., 2013; Monk et al., 2009) . Although several zf gpr126 mutant alleles have been recovered in genetic screens (Pogoda et al., 2006) , none specifically affect the tethered agonist sequence. Therefore, we utilized transcription-activator-like effector nucleases (TALENs) to target this region ( Figures S3A and S3B ). We isolated a mutant, gpr126 stl215 , which lacks only two codons (Gly 831 -Ile 832 ) within the tethered agonist sequence (Figures 4A,  4B, and S3C) . The gpr126 stl215 mutants were grossly normal compared with WT animals ( Figure S3D ), but developed swollen ears ( Figure 4C ), failed to express myelin basic protein (mbp, a The highest agonistic efficacy was detected for a peptide containing 16 aa (p16). Negative controls: eV and GPR126-P2Y 12 -DGPS-CTF mutant. Basal cAMP levels were 3.8 ± 1.6 nM. (B) Different p16 concentrations were tested on WT P2Y 12 , WT GPR126, and P2Y 12 -DGPS-CTF. Inset: the concentration-response curve of p16 at WT GPR126 revealed an EC 50 > 400 mM. Basal eV levels were 3.2 ± 0.7 nM. (C) COS-7 cells endogenously express low levels of GPR126 (see Figure S2C ). Endogenous and transfected GPR126 were knocked down with primate GPR126specific siRNA as shown by abolished cAMP formation (x-fold over eV; basal cAMP: 5.5 ± 2.2 nM). This was confirmed by a DMR assay (Epic biosensor measurements; Figure S2D ) and reduced cell-surface ELISA (see Figure S2E ). (D) The specificity of p16 was confirmed on endogenous GPR126. Mutation of position 6 (Leu 6 Ala) abolished the response of p16 in Epic measurements, as indicated by a picometer (pm) shift of the resonant wavelength caused by DMR within the cell. (E) A systematic alanine scan within the p16 peptide showed that the six aa downstream of Thr 813 are required for receptor activation. Basal cAMP levels were 3.8 ± 1.6 nM. (F) p16 Gly 4 Ala (1 mM) blocked activation of GPR126 by p16 (500 mM). Basal cAMP levels were 18.7 ± 9.4 nM. Data are shown as means ± SEM of three independent experiments, each performed in triplicate. Statistics were obtained by two-way ANOVA and Bonferroni post hoc test: *p < 0.05; **p < 0.01; ***p < 0.001. marker of mature Schwann cells) along the posterior lateral line nerve (PLLn) ( Figures 4D and 4E) , and did not myelinate peripheral axons (Figures S3E-S3H) . These defects completely phenocopy the previously published gpr126 st49 mutant, which has an early stop codon in the GAIN domain upstream of the GPS motif ( Figure 4B ; Monk et al., 2009) . Importantly, the Gly 831 -Ile 832 deletion introduced by the gpr126 stl215 mutation did not alter the cell-surface expression of the receptor (Figures S4A and  S4B) . Therefore, we conclude that the phenotypes observed in gpr126 stl215 mutants are caused by loss of a functional tethered agonist.
Finally, we tested whether p16 serves as an agonist for endogenous Gpr126 in vivo, using zf PLLn mbp expression as an assay. The gpr126 st63 allele contains a point mutation in the first extracellular loop of the 7TM that converts a conserved cysteine residue to tyrosine (C 917 Y; Figure 4B ; Monk et al., 2009 ). This mutant receptor shows reduced cell-surface expression compared with the WT (60% of WT levels; Figure S4A ) and a concomitant reduction in basal activity ( Figure S4B ). In vivo, mbp expressed is reduced, but not absent, along the PLLn (Pogoda et al., 2006) . In contrast, mbp expression is completely (C) Specificity of the p16 (GPR126) and the p13 (GPR133) peptides were verified using WT P2Y 12 , WT GPR126, and WT GPR133 as controls. p16 peptide activated WT GPR126 and P2Y 12 -DGPS-CTF(GPR126), whereas it exhibited unspecific activity in control receptors due to endogenous expression of GPR126 in COS-7 cells ( Figure S2C ). The p13 peptide specifically activated WT GPR133 and P2Y 12 -DGPS-CTF(GPR133). Basal cAMP levels were 3.0 ± 0.8 nM. Data are shown as means ± SEM of three independent experiments, each performed in triplicate. Statistics were obtained by two-way ANOVA and Bonferroni post hoc test: *p < 0.05; **p < 0.01; ***p < 0.001. See also Table S1 . absent along the PLLn of the strong lossof-function gpr126 st49 and gpr126 stl215 mutants (Figures 4D and 4E) . Therefore, we predicted that the gpr126 st63 allele produces a hypomorphic Gpr126 protein with reduced signaling capability. Accordingly, our ultrastructural analysis revealed that gpr126 st63 mutants can myelinate axons in the PLLn, although fewer axons are myelinated than in the WT (Figures S4C and S4D) (S.C.P. and K.R.M., unpublished data).
Because we can infer that gpr126 st63 mutants possess a partially functional 7TM, we hypothesized that exogenous addition of p16 could increase the signaling of endogenous hypomorphic Gpr126. This assay is feasible given that small molecules, including peptides, can freely diffuse into the developing larva in the presence of a carrier (Morash et al., 2011) , and because the functionally important positions in p16 are almost 100% identical between Danio rerio and Homo sapiens ( Figure S2F ). Indeed, p16 was able to activate WT zf Gpr126 in in vitro cAMP assays ( Figure S4B ). Therefore, we treated gpr126 st63 mutants with 100 mM p16 in DMSO from 50-55 hr postfertilization, which constitutes a temporal window in which cAMP elevation by forskolin administration can rescue myelination in gpr126 st49 mutants (Glenn and Talbot, 2013; Monk et al., 2009) . We then qualitatively scored mbp expression in the PLLn (Figure 4A ). As a negative control, we treated siblings with DMSO and observed normal PLLn mbp expression in the WT (gpr126 +/+ or gpr126 st63/+ ) and reduced or absent mbp in hypomorphic gpr126 st63/st63 mutants (Figures 4F-4K ). Treatment with 100 mM p16 caused no significant change in WT larvae, but significantly rescued mbp expression in gpr126 st63/st63 hypomorphs (0% ''strong'' or ''some'' in gpr126 st63/st63 + DMSO versus 44% ''strong'' or ''some'' in gpr126 st63/st63 + p16; Figures  4H, 4J, and 4K) . To test whether this effect is specific to Gpr126 signaling, we also assayed strong loss-of-function gpr126 st49 mutants, which presumably do not express a 7TM . Exogenous treatment of gpr126 st49 mutants with 100 mM p16 did not rescue mbp expression in the PLLn (Figure 4K) , indicating that p16 signals through the 7TM. Together, these loss-and gain-of-function experiments in zf demonstrate the in vivo relevance of tethered peptide activation of aGPCRs.
DISCUSSION
We define a common intramolecular agonistic domain for the aGPCRs GPR126 and GPR133 that comprises a sequence between the GPS cleavage site and TM1. Because of its activating nature and its position at the very C terminus of the ECD, we refer to this agonistic sequence as the ''Stachel sequence'' (Stachel is the German word for stinger). Our analysis of gpr126 stl215 suggests that Stachel-mediated activation of Gpr126 is essential for Schwann cell myelination in zf ( Figures 4C-4E and S3E-S3G); however, the in vivo mechanisms that unmask this tethered agonistic domain are unknown. GAIN domain crystal structures revealed that the Stachel sequence lies buried between two b sheets (Araç et al., 2012) . We and others have shown that CTF-only truncation mutant aGPCRs possess increased basal activity ( Figures 1C-1E ; Okajima et al., 2010; Paavola et al., 2011 Paavola et al., , 2014 Yang et al., 2011) . In all of these studies, the critical GAIN domain b sheets were deleted along with the rest of the NTF, presumably exposing the Stachel sequence. Therefore, structural changes in vivo due to extracellular molecules interacting with the ECD (Langenhan et al., 2013; Liebscher et al., 2013) or even mechanical removal of the NTF may expose the Stachel sequence to activate the 7TM. The low affinity of the Stachel sequence to the 7TM suggests a fast on/off ligand-receptor interaction and supports activation by mechanical signals (Karpus et al., 2013) .
Peptide agonists usually bind to their cognate receptor in a sequential two-step mechanism (Monteclaro and Charo, 1996) . The first step requires high-affinity interactions with extracellular loop regions, whereas the second step is mediated by low-affinity interactions with the helix bundle, promoting receptor activation. Based on our findings, the first step is not required for aGPCRs, because the activating peptide is part of the receptor's own ECD and therefore covalently bound to the 7TM. In the second step of our model of aGPCR activation, the Stachel sequence is predicted to interact with extracellular loops and upper helix bundles as in other peptide/peptide-GPCR pairs (Thompson et al., 2012) , which requires a low affinity. This model is also consistent with protease-activated receptors in which thrombin cleaves the receptor's N terminus and exposes an activating tethered agonist (Vu et al., 1991) .
Large ECDs are not unique to the aGPCR family. The ectodomains of glycoprotein hormone receptors (the rhodopsin-like GPCR class) are also composed of several hundred aa forming leucine-rich repeat domains. In glycoprotein hormone receptors, a conserved module termed the hinge region (Sangkuhl et al., 2002) connects the ECD to the 7TM in a manner similar to that observed for the GPS domain in aGPCRs. Although the interspaced hinge region does not share the predicted 3D structural identity with the GPS motif, both the hinge region and the GPS motif possess multiple disulfide bonds that form at least two loops of the polypeptide chain (Araç et al., 2012) . Interestingly, hinge-region mutations of glycoprotein hormone receptors can activate these rhodopsin-like GPCRs, suggesting an ''intramolecular agonistic unit'' (Krause et al., 2012) . Similarly, mutations in Cys 775 , Cys 794 , Cys 807 , and Cys 809 of GPR126, which normally form disulfide bridges in the GAIN domain, displayed constitutive activity in cAMP assays ( Figures S4E and S4F) . These data provide further evidence that structural changes in the GPS region promote activation via the Stachel sequence.
Our results are compatible with an activation scenario of aGPCRs in which an intramolecular agonistic domain (the Stachel sequence) is unmasked upon structural changes of the ECD, which subsequently triggers 7TM-mediated activation of G protein-signaling cascades (Figures S1B [cis signaling] and S4G). Recent evidence indicates that the ECD of GPR126 and other aGPCRs can mediate biological functions independently of the 7TM (trans signaling) Prö mel et al., 2012) . Our discovery may facilitate attempts to distinguish between trans-and cis-dependent functions; for example, phenotypic perturbations in model organisms through peptide agonists could be attributed to cis signaling of the receptor (e.g., Figures  4F-4K ). Our study defines a signaling modality for aGPCRs and lays the foundation for rational ligand design to promote a deeper understanding of the physiology and therapeutic usefulness of this emerging class of GPCRs.
EXPERIMENTAL PROCEDURES aGPCR Constructs and Functional Assays
Epitope-tagged, full-length human aGPCR sequences were inserted into pcDps, and mutant aGPCRs were generated by PCR (Table S1 ). For functional assays, transfected COS-7 cells were split into 48-well plates and cAMP concentrations were determined with the Alpha Screen cAMP assay kit (PerkinElmer Life Sciences) according to the manufacturer's protocol. To measure label-free receptor activation, a DMR assay (Epic biosensor measurements; Corning Life Sciences) with COS-7 cells endogenously expressing GPR126 was performed as previously described (Schrö der et al., 2010) . To estimate cell-surface and total expression of receptors carrying N-terminal HA and C-terminal FLAG tags, ELISA was used (Schö neberg et al., 1998) . Assay data were analyzed with GraphPad Prism version 6.0 for Windows (GraphPad Software) and statistical details are given in each figure legend.
Peptide Synthesis
Solid-phase peptide synthesis of the peptides was performed on an automated peptide synthesizer (MultiPep; Intavis AG) using standard Fmoc chemistry.
Zebrafish Studies
Adult zebrafish were maintained in the Washington University Zebrafish Consortium facility in accordance with institutional animal protocols (http:// zebrafish.wustl.edu/husbandry.htm). Embryos were collected from heterozygous gpr126 mutant adults, and mutant larvae were compared with WT siblings for all assays. See the Supplemental Experimental Procedures for details on TALEN mutagenesis, in situ hybridization, transmission electron microscopy, and peptide treatment. (D) Lateral view of whole-mount in situ hybridization (WISH) of zf larvae at 4 dpf. The posterior lateral line nerve (PLLn) is marked with an arrow; mbp expression in the CNS is indicated with an arrowhead. mbp expression can be observed in the CNS, but not in the PLLn of gpr126 stl215/215 mutant larvae (st215). (E) Quantification of the swollen ear phenotype and PLLn mbp expression out of the total number of larvae scored per genotype (WT = gpr126 +/+ and gpr126 stl215/+ ).
